Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage ...

Brii Biosciences Ltd. engages in advancing therapies for significant infectious diseases and other illnesses which have significant public health burdens. The firm also focuses on developing ...